November 1, 2013
The Master Class XIV • 2013
Disclaimer
The recommendations provided from the authors were obtained on November 1, 2013. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology (CAG) for up-to-date treatment options.
Learning Objectives
The educational objective of the Mentoring in IBD program is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD. Participants in the program will:
- Discuss the efficacy and safety data for vedolizumab and golimumab in ulcerative colitis and position these agents in current and future algorithms of care
- Focus on diagnosis, treatment and management of chronic refractory pouch dysfunction
- Consider the role of the microbiome in Crohn’s disease and ulcerative colitis and how a clinician can manipulate it
- Examine the way we do surveillance of cancer in IBD and how to implement change
- Investigate the use of immunosuppressives and biologics before, during and after pregnancy
- Survey current IBD literature
New Treatments in IBD: Vedolizumab and Golimumab in UC
Presented by Brian Feagan, MD
State-of-the-art Plenary Presentation
Chronic Refractory Pouch Dysfunction
Presented by Bo Shen, MD
State-of-the-art Plenary Presentation
The Microbiome and Probiotics in IBD
Presented by Fergus Shanahan, MD
State-of-the-art Plenary Presentation
Colon Cancer in IBD: Focus on Surveillance
Presented by Marietta Iacucci
State-of-the-art Plenary Presentation